Equities

RaQualia Pharma Inc

4579:TYO

RaQualia Pharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)558.00
  • Today's Change-4.00 / -0.71%
  • Shares traded25.20k
  • 1 Year change-25.10%
  • Beta1.1706
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3,7653,9262,659
Total Receivables, Net6036021,205
Total Inventory1488.5011
Prepaid expenses255198106
Other current assets, total1868722
Total current assets4,9574,8224,004
Property, plant & equipment, net574391299
Goodwill, net------
Intangibles, net302434
Long term investments1,231988888
Note receivable - long term------
Other long term assets118.189.16
Total assets6,8726,2585,234
LIABILITIES
Accounts payable5412846
Accrued expenses5460100
Notes payable/short-term debt000
Current portion long-term debt/capital leases774622
Other current liabilities, total204260233
Total current liabilities389494401
Total long term debt29117718
Total debt36822239
Deferred income tax--2.7516
Minority interest------
Other liabilities, total718712
Total liabilities752761446
SHAREHOLDERS EQUITY
Common stock2,6682,2662,257
Additional paid-in capital2,8572,4552,447
Retained earnings (accumulated deficit)47578160
Treasury stock - common(0.02)(0.02)(0.02)
Unrealized gain (loss)120(5.57)24
Other equity, total0.000.000.00
Total equity6,1205,4974,788
Total liabilities & shareholders' equity6,8726,2585,234
Total common shares outstanding222121
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.